bluebird bio (BLUE)
(Delayed Data from NSDQ)
$0.94 USD
-0.08 (-7.57%)
Updated Aug 7, 2024 04:00 PM ET
After-Market: $0.93 -0.01 (-1.36%) 7:58 PM ET
3-Hold of 5 3
F Value F Growth A Momentum F VGM
Brokerage Reports
0 items in cart
bluebird bio, Inc. [BLUE]
Reports for Purchase
Showing records 461 - 480 ( 533 total )
Company: bluebird bio, Inc.
Industry: Medical - Biomedical and Genetics
Healthcare -Biotechnology: Catalyst Tracker Through Mid-15
Provider: Roth Capital Partners, Inc.
Analyst: CHATTOPADHYAY D
Company: bluebird bio, Inc.
Industry: Medical - Biomedical and Genetics
Healthcare: Biotechnology: Its Yogi Berra All Over Again
Provider: Roth Capital Partners, Inc.
Analyst: CHATTOPADHYAY D
Company: bluebird bio, Inc.
Industry: Medical - Biomedical and Genetics
Prepping for a Midyear SCD Data Readout, Target to $145
Provider: Roth Capital Partners, Inc.
Analyst: CHATTOPADHYAY D
Company: bluebird bio, Inc.
Industry: Medical - Biomedical and Genetics
MORNING SUMMARY
Provider: Roth Capital Partners, Inc.
Company: bluebird bio, Inc.
Industry: Medical - Biomedical and Genetics
Healthcare - Biotechnology: Key Takeaways From the 27th Annual Conference
Provider: Roth Capital Partners, Inc.
Analyst: CHATTOPADHYAY D
Company: bluebird bio, Inc.
Industry: Medical - Biomedical and Genetics
4Q14 EPS, Awaiting SCD Readout, Reiterate Outperform
Provider: WEDBUSH SECURITIES INC.
Analyst: NIERENGARTEN D
Company: bluebird bio, Inc.
Industry: Medical - Biomedical and Genetics
MORNING SUMMARY
Provider: Roth Capital Partners, Inc.
Company: bluebird bio, Inc.
Industry: Medical - Biomedical and Genetics
All Eyes on SCD Data and Beta- Thalassemia Regulatory Strategy
Provider: Roth Capital Partners, Inc.
Analyst: CHATTOPADHYAY D
Company: bluebird bio, Inc.
Industry: Medical - Biomedical and Genetics
MORNING SUMMARY
Provider: Roth Capital Partners, Inc.
Company: bluebird bio, Inc.
Industry: Medical - Biomedical and Genetics
Annuity-Based Payment Structures, An Idea Whose Time Has Come
Provider: Roth Capital Partners, Inc.
Analyst: CHATTOPADHYAY D
Company: bluebird bio, Inc.
Industry: Medical - Biomedical and Genetics
Biotechnology/Biopharma: 27th Annual ROTH Conference: Healthcare Track Preview
Provider: Roth Capital Partners, Inc.
Analyst: CHATTOPADHYAY D
Company: bluebird bio, Inc.
Industry: Medical - Biomedical and Genetics
MORNING SUMMARY
Provider: Roth Capital Partners, Inc.
Company: bluebird bio, Inc.
Industry: Medical - Biomedical and Genetics
Company: bluebird bio, Inc.
Industry: Medical - Biomedical and Genetics
Regulators Warming Up To Gene Therapy With A BTD For LentiGlobin
Provider: Roth Capital Partners, Inc.
Analyst: CHATTOPADHYAY D
Company: bluebird bio, Inc.
Industry: Medical - Biomedical and Genetics
MORNING SUMMARY
Provider: Roth Capital Partners, Inc.
Company: bluebird bio, Inc.
Industry: Medical - Biomedical and Genetics
Gene Therapy/Gene Editing Going Mainstream, Reiterate Focus Pick
Provider: Roth Capital Partners, Inc.
Analyst: CHATTOPADHYAY D
Company: bluebird bio, Inc.
Industry: Medical - Biomedical and Genetics
Raising Estimated LentiGlobin Price, Proof-of-Concept in Sickle Cell Should Drive to New Heights.
Provider: WEDBUSH SECURITIES INC.
Analyst: NIERENGARTEN D
Company: bluebird bio, Inc.
Industry: Medical - Biomedical and Genetics
MORNING SUMMARY
Provider: Roth Capital Partners, Inc.
Company: bluebird bio, Inc.
Industry: Medical - Biomedical and Genetics
SCD, CAR T, And B-Thal Regulatory Strategy Are 2015 Focus Items
Provider: Roth Capital Partners, Inc.
Analyst: CHATTOPADHYAY D
Company: bluebird bio, Inc.
Industry: Medical - Biomedical and Genetics
MORNING SUMMARY
Provider: Roth Capital Partners, Inc.